



CY 2025 Annual Report

**Mississippi State Department of Health
Office of Medical Cannabis**

**Mississippi Department of Revenue
Alcohol Beverage Control Division**

www.MMCP.ms.gov



[Patients & Caregivers](#) ▾ [Businesses](#) ▾ [Compliance](#) ▾ [About](#) ▾

[LICENSING PORTAL](#)

Mississippi Medical Cannabis Program

The Mississippi Medical Cannabis Program (MMCP) provides a safe and accessible program that meets the needs of patients and the public health and safety of all Mississippi residents.

[APPLY FOR LICENSE/REGISTRATION](#)

Verify License
Validate License Holders

Transparency Portal
Cannabis Transparency Portal

Business Search
Browse Registered Establishments

The Mississippi Medical Cannabis Program remains steadfast in its commitment to ensuring safe, regulated access to medical cannabis for qualified patients, while maintaining rigorous compliance standards that reinforce industry accountability and advance community well-being through education and public awareness.

The performance period for the data collected in this report is January 1, 2025, through December 15, 2025, unless otherwise noted.

Table of Contents

- **Executive Summary**
- **Financial Overview**
- **Calendar Year 2025 Program Statistics**

Executive Summary

In Calendar Year (CY) 2025, Mississippi's medical cannabis program demonstrated strong growth, improved fiscal performance, and continued maturation, while maintaining relatively efficient regulatory operations. The program expanded across key measures including tax revenues, patient participation, and workforce engagement, signaling sustained demand and increasing market stability.

Fiscal Performance and Government Oversight

Cannabis-related tax revenues increased significantly year over year. Excise tax collections rose from approximately \$1.64 million in CY 2024 to \$2.18 million in CY 2025, while cannabis sales tax revenue grew from \$6.18 million to \$9.00 million. These gains reflect robust retail activity and continued program adoption.

Regulatory costs remained comparatively modest relative to revenue growth. The Mississippi Department of Revenue (MDOR) incurred total CY 2025 expenses of \$51,228, primarily related to equipment, commodities, and contractual services. Fines assessed by MDOR increased to \$23,500, while fines assessed by the Mississippi State Department of Health (MSDH) declined substantially from \$275,000 in CY 2024 to \$135,000 in CY 2025. MSDH program expenses totaled \$6.72 million, largely driven by contractual services and personnel costs supporting program administration.

Patient and Practitioner Participation

Patient participation increased markedly. Active patient counts rose from 49,626 in CY 2024 to 66,041 in CY 2025, representing significant year-over-year growth. Application volumes remained strong, with more than 33,000 new patient applications and a similar number of renewals processed during the year. No patient cards were revoked in CY 2025, aside from deactivations initiated by certifying practitioners.

The number of active certifying practitioners remained stable at 259, including physicians, nurse practitioners, and optometrists, ensuring continued access to certification services statewide.

Industry and Market Dynamics

The licensed industry experienced selective shifts. While certain license categories such as cultivation, dispensaries, transportation, and testing laboratories declined modestly, other areas expanded. Micro-processing licenses, research licenses, and workforce participation increased, with work permits rising from 4,661 to 5,862. These changes suggest consolidation in some sectors alongside diversification and professionalization in others.

Retail sales remained steady throughout the year, with consistent quarterly and monthly performance. Flower products continued to represent the most affordable option on average (\$22.50 per unit), while specialized products, including transdermal patches, commanded higher prices (\$69.16 per unit), reflecting varied patient needs and product differentiation.

Medical Trends

Chronic pain and post-traumatic stress disorder (PTSD) remained the most commonly certified qualifying conditions. Notably, Type 2 Diabetes Mellitus with neurological complications rose in ranking among qualifying conditions in CY 2025, indicating evolving clinical utilization patterns within the program.

Overall Assessment

Overall, CY 2025 marked a year of strong fiscal performance, growing patient participation, and increasing market maturity for the Mississippi Medical Cannabis Program. Revenue growth outpaced regulatory expenses, patient access expanded, and the program continued to adapt to changing medical and market dynamics, positioning it for continued stability and long-term sustainability.


President's Executive Order

On December 18, 2025, President Trump signed an executive order titled *Increasing Medical Marijuana and Cannabidiol Research*. The order directs the Attorney General and the Department of Justice (DOJ) to take “all necessary steps” to reschedule marijuana from Schedule I to Schedule III under the federal Controlled Substances Act.

At this time, the DOJ has not issued a final rule to implement the rescheduling. The timeline for such a rule remains uncertain, and marijuana continues to be classified as a Schedule I substance until a final rule is published. MMCP will continue to monitor developments and assess any potential impacts on the state's program and research activities.

Financial Overview

Fees Collected & Expenses



Taxes Collected

	CY 2024	CY 2025 (current)
Cannabis Excise Tax Holding	\$1,641,896.40	\$2,177,979.93
Clearing Account - Cannabis	\$2,284.48	\$2,161.38
Cannabis Excise Tax Total	\$1,639,711.92	\$2,180,141.31
Sales Tax – Cannabis Rate Code 83		
Cannabis Sales Tax	\$6,176,377.51	\$9,002,940.86

**MSDH Expenses
1/1/2025 – 12/29/2025**

	SFY 2025	SFY 2026	CY 2025 Total
Salaries & Fringe	\$1,013,529.37	\$169,847.90	\$1,183,377.27
Travel	\$33,398.73	\$4,907.73	\$38,306.46
Contractual	\$3,549,886.46	\$1,074,238.62	\$4,624,125.08
Commodities	\$119,619.78	\$16,661.92	\$136,281.70
Equipment	\$99,286.21	\$0	\$99,286.21
Indirect Costs	\$540,000	\$95,106.92	\$635,106.92
CY 2025 Total	\$5,355,720.55	\$1,360,763.09	\$6,716,483.64

MSDH Fines Assessed

CY 2024	CY 2025 (current)
\$275,000	\$135,000

**MDOR Expenses
1/1/2025 – 12/29/2025**

	SFY 2025	SFY 2026	CY 2025 Total
Salaries	\$0	\$0	\$0
Travel	\$0	\$0	\$0
Contractual	\$10,715	\$0	\$10,715
Commodities	\$11,618	\$0	\$11,618
Equipment/Vehicles	\$28,895	\$0	\$28,895
CY 2025 Total	\$51,228	\$0	\$51,228

MDOR Fines Assessed

CY 2024	CY 2025 (current)
\$0	\$23,500

CY 2025 Program Statistics

	Submitted	Approved
New Patient Applications	33356	33333
Patient Application Renewals	33377	33033
New Caregiver Applications	157	157
Caregiver Application Renewals	90	90

CY 2024 Active Certifying Practitioner Count (as of 12/15/2024)	CY 2025 Active Certifying Practitioner Count (as of 12/15/2025 - current)
258	259*

* Physicians – 117, Nurse Practitioners – 137, Optometrists – 5

CY 2024 Active Patient Count (as of 12/30/2024)	CY 2025 Active Patient Count (as of 12/15/2025 - current)
49,626	66,041

There were no patient cards revoked in calendar year 2025, excluding cards deactivated at practitioners' requests because the cardholder no longer met certification requirements.


Entity Type	CY 2024	CY 2025 (current)
Cultivation	61	53
Micro-Cultivation	62	57
Processing	18	17
Micro-Processing	16	20
Transportation	20	16
Waste Disposal	6	5
Work Permits	4661	5862
Testing Labs	4	2
Research	0	1
Dispensaries	200	171*

*This number was pulled as of 12/29/2025.


Top 10 Qualifying Conditions Certified

CY 2024	CY 2025 (current)
1. Chronic Pain	1. Chronic Pain
2. Post-Traumatic Stress Disorder (PTSD)	2. Post-Traumatic Stress Disorder (PTSD)
3. Spinal Cord Disease or Severe Injury	3. Spinal Cord Disease or Severe Injury
4. Cancer	4. Cancer
5. Muscle Spasms	5. Muscle Spasms
6. Long Term Use of Opiate Analgesic (current)	6. Type 2 Diabetes Mellitus with Neurological Complications
7. Type 2 Diabetes Mellitus with Neurological Complications	7. Severe Nausea
8. Nausea	8. Seizure
9. Glaucoma	9. Pain Refractory to Appropriate Opioid Management
10. Epilepsy and Recurrent Seizures	10. Glaucoma


**Retail Sales by Quarter
1/1/2025 – 12/29/2025**



**Retail Sales by Month
1/1/2025 – 12/29/2025**



Market Share per Unit Category Type 1/1/2025 – 12/29/2025



**Average Cost Per MMCEU
1/1/2025 – 12/29/2025**

Product Category Name	Unit Average
Bud/Flower/Shake/Trim	\$22.50
Concentrate (Each)	\$44.84
Infused Edible	\$29.18
Raw Pre-Rolls	\$27.45
Conc. Infused Pre-Rolls	\$24.56
Concentrate	\$43.83
Infused Flower	\$20.78
Topical (Each)*	\$27.65
Transdermal Patch	\$69.16
Infused Non-Edible	\$39.26
Suppository (Each)*	\$17.63

*Topicals and Suppository items do not calculate towards item allotments. Cost for these are calculated by individual retail item averages.